Pulmonary Embolism

Embolism : Impaction of a thrombus (that has travelled from elsewhere in the body through the bloodstream), or foreign matter in the pulmonary vascular bed.

Infarction : The pathological changes which develop in the lung as a result of pulmonary embolism.

Etiology

Three primary influences predispose a patient to thrombus formation; these form the so-called Virchow triad, which consists of : Endothelial injury Stasis or turbulence of blood flow

Blood hypercoagulability

Risk factors

- Venous stasis
- Hypercoagulable states
- Immobilization
- Surgery and trauma
- Pregnancy
- Oral contraceptives and estrogen replacement
- Malignancy

Hereditary factors: Antithrombin III deficiency, Protein S&C deficiency, Plasminogen&Fibrinogen abnormality
Acute medical illness: AIDS, CHF, SLE. When a pulmonary embolism is identified, it is characterized as acute or chronic. In terms of pathologic diagnosis,

An embolus is acute if it is situated centrally within the vascular lumen or if it occludes a vessel.

An embolus is chronic if it is eccentric and contiguous with the vessel wall it reduces the arterial diameter by more than 50%, evidence of recanalization within the thrombus is present, and an arterial web is present.



Respiratory consequences

Increased alveolar dead space and hypoxemia due to <u>ventilation-perfusion</u> <u>mismatch</u>, <u>intrapulmonary shunts</u>, reduced cardiac output.

Pulmonary infarction is an uncommon consequence because of the bronchial arterial collateral circulation. Hemodynamic consequences

Increment in pulmonary vascular resistance, which, in turn, increases the right ventricular afterload. If the afterload is increased severely, right ventricular failure may ensue.

Clinical Features

Size of the embolus and blood vessel occluded. State of the lung. Associated diseases

Massive Pulmonary Embolism (MPE) Pulmonary Infarction (PI) Obliterative Pulmonary Hypertension





Pulmonary emboli in main branches of pulmonary arteries

Signs and symptoms

•No obvious symptoms at presentation.

- Pleuritic chest painShortness of breath
- •Hypoxia.

Gradually progressive dyspneaSudden hemodynamic collapse

Atypical symptoms

- Hemoptysis
- Seizures
- •Syncope
- Abdominal pain
- •Fever
- •Wheezing
- Decreasing level of consciousness
- Atrial fibrillation
- Delirium (in elderly patients)

Tachcardia(more than 100/ min)
Tachypnoea
Jaundice
Cyanosis

Consolidation, Diminished Intensity of Breath Sounds, Crepitus
Wheezing Chest
Pleural Rub
Signs of Pleural Effusion Differential Diagnosis

•Myocardial Infarction.
•Dissecting Aortic Aneurysm.
•Peumothorax.
•Major Pulmonary Collapse.
•Perforating Peptic Ulcer.
•Acute Pancreatitis.



Clinical scoring systems to determine the clinical probability before proceeding with testing.

- Tachypnea
- •Rales
- Accentuated second heart sound
- Tachycardia (heart rate >100/min)
- •Fever
- •Clinical signs and symptoms suggesting thrombophlebitis
- Cardiac murmur
- Cyanosis



Perform diagnostic testing on symptomatic patients with suspected pulmonary embolism to confirm or exclude the diagnosis.

D-dimer testing: non specific
Arterial blood gases
Serum troponin levels
Brain natriuretic peptide

Imaging studies 1- Chest x-ray

Westermark sign,



Hampton's hump



3- Helical CT: Rapid and noninvasive



-ECG: (S1Q3T3) & Echocardiography



-Pulmonary angiography



-Venography & Duplex ultrasonography for deep vein thrombosis

Transducer



Copyright TVB 2055

-ventilation perfusion scan: (V/Q)





Thrombolysis Alteplase Reteplase Urokinase Streptokinase

Used for : 1- Haemodynamically unstable patients

2- Cardiac arrest.

This treatment is

- Expensive, not available.
- Side effects are bleeding and allergy

Anticoagulation

1- Heparin : 5000 - 25 000 U iv Bolus
Followed up: Partial Thromboplastin Time (PTT).kept at
1.5 - 2.5
Antidote: is Protamine Sulphate
Used for For 7 - 10 days.

2- Low MV heparin.

- •Low-Molecular-Weight-Heparin:
- •Can be given Subcutaneously.
- •Longer duration of Anticoagulant effect.
- •PTT monitoring is not necessary.
- •Enoxaparin: 1 mg/kg every 12h.



3-Oral Anticoagulant

Warfarin:

- Act after 2-3days
- Monitoring by prothrombin time& activity and INR.
- INR kept at 2.5 (theraputic level)
- Duration of treatment 3-6 months.

4- Surgical options

•Catheter embolectomy & fragmentation or surgical embolectomy

Placement of vena cava filters

5- Adjuvants

•Oxygen, Antibiotics, Rest in bed.

